Enzychem Lifesciences Corporation (KOSDAQ: 183490)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,290.00
-36.00 (-2.71%)
Dec 20, 2024, 9:00 AM KST
-28.85%
Market Cap 102.99B
Revenue (ttm) 82.07B
Net Income (ttm) -7.86B
Shares Out 79.84M
EPS (ttm) -94.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,426
Open 1,328.00
Previous Close 1,326.00
Day's Range 1,270.00 - 1,349.00
52-Week Range 1,047.00 - 2,220.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 21, 2025

About Enzychem Lifesciences

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 1999
Employees 122
Stock Exchange KOSDAQ
Ticker Symbol 183490
Full Company Profile

Financial Performance

In 2023, Enzychem Lifesciences's revenue was 76.04 billion, an increase of 185.46% compared to the previous year's 26.64 billion. Losses were -9.33 billion, -62.59% less than in 2022.

Financial Statements

News

There is no news available yet.